Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ГБУЗ «Областная психиатрическая больница им. К. Р. Евграфова» 440026, г. Пенза, ул. Лермонтова, 28. skrembler@mail.ru
Список исп. литературыСкрыть список 1. WHO Collaborating Centre for Drug Statistics Methodology [Electronic resource]. URL: http://www.whocc.no. (access date: 17.11.2019). 2. Государственный реестр лекарственных средств [Электронный ресурс]. URL: http://grls.rosminzdrav.ru. (Дата обращения: 17.11.2019.) / Gosudarstvennyj reestr lekarstvennyh sredstv [Elektronnyj resurs]. URL: http://grls.rosminzdrav.ru. (Data obrashcheniya: 17.11.2019) [in Russian]. 3. Brunton L, Chabner B, Knollman B. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York: McGraw-Hill Professional, 2010. 4. Massot O, Rousselle JC, Fillion MP et al. 5-HT1B Receptors: A Novel Target for Lithium: Possible Involvement in Mood Disorders. Neuropsychopharmacology. 1999 Oct; 21 (4): 530–41. 5. Scheuch K, Höltje M, Budde H et al. Lithium modulates tryptophan hydroxylase 2 gene expression and serotonin release in primary cultures of serotonergic raphe neurons. Brain research. 2010 Jan 11; 1307: 14–21. 6. Malhi GS, Tanious M, Das P et al. Potential mechanisms of action of lithium in bipolar disorder. Current understanding. CNS Drugs. 2013 Feb; 27 (2): 135–53. 7. Brunello N, Tascedda F. Cellular mechanisms and second messengers: Relevance to the psychopharmacology of bipolar disorders. The International Journal of Neuropsychopharmacology. 2003 Jun; 6 (2): 181–9. 8. Malhi GS, Masson M, Bellivier F. The Science and Practice of Lithium Therapy. Switzerland: Springer International Publishing. 2017. P. 61. 9. Granger P, Biton B, Faure C et al. Modulation of the gamma-aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoin. Molecular Pharmacology. 1995 Jun; 47 (6): 1189–96. 10. Dailey JW, Reith ME, Steidley KR et al. Carbamazepine-induced release of serotonin from rat hippocampus in vitro. Epilepsia. 1998 Oct; 39 (10): 1054–63. 11. Dailey JW, Reith ME, Yan QS et al. Carbamazepine increases extracellular serotonin concentration: lack of antagonism by tetrodotoxin or zero Ca2+. European Journal of Pharmacology. 1997 Jun 11; 328 (2-3): 153–62. 12. Kawata Y, Okada M, Murakami T et al. Pharmacological discrimination between effects of carbamazepine on hippocampal basal, Ca(2+)- and K(+)-evoked serotonin release. British Journal of Pharmacology. 2001 Jun; 133 (4): 557–67. 13. Kay HY, Greene DL, Kang S et al. M-current preservation contributes to anticonvulsant effects of valproic acid. The Journal of Clinical Investigation. 2015 Oct 1; 125 (10): 3904–14. 14. Chang P, Walker MC, Williams RS. Seizure-induced reduction in PIP3 levels contributes to seizure-activity and is rescued by valproic acid. Neurobiology of Disease. 2014 Feb; 62: 296–306. 15. Kostrouchova M, Kostrouch Z, Kostrouchova M. Valproic acid, a molecular lead to multiple regulatory pathways. Folia Biologica. 2007; 53 (2): 37–49. 16. Chiu CT, Wang Z, Hunsberger JG et al. Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacological Reviews. 2013 Jan 8; 65 (1): 105–42. 17. Cade JF. Lithium salts in the treatment of psyhotic excitement. The medical Journal of Australia. 1949; 10: 349. 18. Mitchell PB, Hadzi-Pavlovic D. Lithium treatment for bipolar disorder. Bulletin of the World Health Organization. 2000; 78 (4): 515–7. 19. Okuma T, Kishimoto A. A history of investigation on the mood stabilizing effect of carbamazepine in Japan. Psychiatry and Clinical Neurosciences. 1998 Feb; 52 (1): 3–12. 20. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2002; 16 (10): 695–714. 21. Shorvon SD, Perucca E, Engel J. The Treatment of Epilepsy. 4th ed. John Wiley & Sons, Incorporated, 2015. 22. Raskin S, Teitelbaum A, Zislin J et al. Adjunctive lamotrigine as a possible mania inducer in bipolar patients. American Journal of Psychiatry. 2006 Jan; 163 (1): 159–60. 23. López-Muñoz F, Shen WW, D'Ocon P et al. A History of the Pharmacological Treatment of Bipolar Disorder. International Journal of Molecular Sciences. 2018 Jul 23; 19 (7): 15. 24. Регистр лекарственных средств России [Электронный ресурс]. URL: http://www.rlsnet.ru. (Дата обращения: 17.11.2019.) / Registr lekarstvennyh sredstv Rossii [Elektronnyj resurs]. URL: http://www.rlsnet.ru (Data obrashcheniya: 17.11.2019) [in Russian]. 25. Рациональный выбор лекарств на основе индекса информационного спроса [Электронный ресурс]. Газета РЛС. 2008. № 3. URL: http://www.rlsnet.ru/news_295.htm. (Дата обращения: 17.11.2019.) / Racional'nyj vybor lekarstv na osnove indeksa informacionnogo sprosa [Elektronnyj resurs]. Gazeta RLS. 2008. №3. URL: http://www.rlsnet.ru/news_295.htm. (Data obrashcheniya: 17.11.2019) [in Russian]. 26. Вышковский Г. Л. Методология оптимального выбора фаз маркетингового воздействия при медиапланировании. Реклама. Теория и практика. 2007. № 02 (20). / Vyshkovskij G.L. Metodologiya optimal'nogo vybora faz marketingovogo vozdejstviya pri mediaplanirovanii. Reklama. Teoriya i praktika. 2007. №02 (20) [in Russian]. 27. Free U.S. Outpatient Drug Usage Statistics [Electronic resource]. ClinCalc DrugStats Database. URL: http://clincalc.com/DrugStats/. (access date: 17.11.2019). 28. Федеральное руководство по использованию лекарственных средств (формулярная система). Под ред. А. Г. Чучалина, Ю. Б. Белоусова, С. П. Голицина и др. Выпуск XIV. М.: Человек и лекарство, 2013. / Federal'noe rukovodstvo po ispol'zovaniiu lekarstvennykh sredstv formuliarnaia sistema). Pod red. A.G.Chuchalina, Iu.B.Belousova, S.P.Golitsina i dr. Vypusk XIV. M.: Chelovek i lekarstvo, 2013 [in Russian]. 29. Benzodiazepine Equivalency Table [Electronic resource]. Revised April 2007. URL: http://benzo.org.uk/bzequiv.htm. (access date: 17.11.2019). 30. Ashton H. Drug newsletter. Northern Regional Health Authority. Newcastle upon Tyne: Wolfson Unit of Clinical Pharmacology Royal Victoria Infirmary [Electronic resource]. 1985 April; 31. URL: http://benzo.org.uk/drcha.htm (access date: 17.11.2019). 31. Bowden CL. Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder. The Journal of Clinical Psychiatry. 2005; 66 Suppl 3: 12–19. 32. Calabrese JR, Shelton MD, Rapport DJ et al. Current research on rapid cycling bipolar disorder and its treatment. Journal of Affective Disorders. 2001 Dec; 67 (1-3): 241–55. 33. Kahn DA, Sachs GS, Printz DJ et al. Medication treatment of bipolar disorder 2000: a summary of the expert consensus guidelines. Journal of Psychiatric Practice. 2000 Jul; 6 (4): 197–211. 34. Chakrabarti S. Thyroid functions and bipolar affective disorder. Journal of Thyroid Research. 2011; 306367:13. 35. WHO Model List of Essential Medicines 18th list (April 2013) (Final Amendments — October 2013) [Electronic resource]. URL: http://www.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf. (access date: 17.11.2019).